Kristine Peterson Buys 13,562 Shares of AVBP
Insider Kristine Peterson purchased 13,562 shares of AVBP on June 18, 2026.
Key Points
- Kristine Peterson bought 13,562 shares of AVBP on June 18, 2026, with shares trading at $31.74 Tuesday.
- Suvretta Capital Management grew its AVBP holdings by 295,048 shares, now totaling 4,401,083 shares worth about $101.5 million.
- Truist Securities maintained a 'buy' rating for AVBP, setting a price target of $45 on May 29, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kristine Peterson, an insider at AVBP, made a notable purchase of 13,562 shares on June 18, 2026. While the transaction price was not disclosed, shares of AVBP traded at approximately $31.74 on Tuesday.
Other Institutional Activity in AVBP
Suvretta Capital Management increased its stake in AVBP by 295,048 shares, bringing its total holdings to 4,401,083 shares valued at about $101.5 million. Infinitum Asset Management also added 25,000 shares, now holding 4,148,923 shares worth approximately $95.7 million. Meanwhile, HHLR Advisors and Orbimed Advisors maintained their positions without change, each holding 3,929,117 and 3,027,328 shares, respectively. FMR LLC reduced its holdings by 687,440 shares, resulting in a total of 3,016,132 shares valued at about $69.6 million.
ArriVent BioPharma, Inc. Stock Up 8.4%
AVBP shares traded near $31.74 on Tuesday. The stock has a varied institutional presence, with several key players adjusting their positions recently.
$AVBP stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at ArriVent BioPharma, Inc.
On June 18, 2026, several insiders, including Kristine Peterson, Chris Nolet, John Hohneker, and Merdad Parsey, each acquired 13,562 shares of AVBP. Earlier in the year, on February 2, James Paul Kastenmayer, the General Counsel, and Winston Kung, the CFO, purchased 130,000 and 140,000 shares, respectively.
Analysts Set New Price Targets
On May 29, 2026, Truist Securities maintained its 'buy' rating on AVBP, setting a price target of $45. Citigroup also maintained its 'buy' rating with a target of $43 on May 13, 2026. Other firms like B. Riley Securities and Oppenheimer have similarly expressed positive outlooks, with price targets of $45 and $50, respectively.
Bottom Line
Kristine Peterson's recent share purchase highlights ongoing insider interest in AVBP. Institutional investors like Suvretta Capital and Infinitum Asset Management have also adjusted their holdings, reflecting varied strategies in response to market conditions. Analysts continue to maintain positive ratings, suggesting confidence in AVBP's potential, though these assessments are based on past data and may not reflect future performance.
Get ArriVent BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AVBP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.